Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Collplant Holdings ( (CLGN) ) just unveiled an update.
On April 9, 2026, Allergan Industrie SAS, an AbbVie company, notified CollPlant that it would terminate their February 2021 development agreement for an rhCollagen-based dermal and soft tissue filler, with the collaboration to end on June 8, 2026. In an April 13, 2026 letter to shareholders, CollPlant framed the termination as an opportunity, saying it is in advanced discussions with several leading strategic partners for new aesthetic collaborations while implementing a cost-reduction plan, including cutting about 50% of its workforce, to extend its cash runway into the fourth quarter of 2026.
The company highlighted ongoing progress in its three core programs, including preclinical development of photocurable regenerative dermal fillers, manufacturing upgrades and partner talks for regenerative breast implants, and the expansion of its rhCollagen bioinks portfolio and North American distribution. Management underscored that strong interest from potential partners and recent scientific validation and logistics expansion support its strategy to reposition CollPlant in the aesthetics and bioprinting markets despite the loss of the AbbVie partnership, with implications for a leaner cost base and greater strategic flexibility going forward.
The most recent analyst rating on (CLGN) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
The score is driven primarily by weak financial performance (losses, inconsistent revenue, and ongoing cash burn) and a bearish technical setup with the stock far below key moving averages. Valuation provides limited support due to negative earnings and no indicated dividend.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies Ltd., based in Rehovot, Israel, is a regenerative and aesthetic medicine company developing products from its proprietary plant-derived recombinant human collagen (rhCollagen). Its core programs span regenerative dermal and soft tissue fillers, regenerative breast implants and rhCollagen-based bioinks for 3D bioprinting, targeting medical aesthetics, tissue engineering and advanced research markets.
Average Trading Volume: 90,712
Technical Sentiment Signal: Sell
Current Market Cap: $5.51M
For an in-depth examination of CLGN stock, go to TipRanks’ Overview page.